NEW YORK, May 5, 2017 /PRNewswire/ --
This morning's research on Stock-Callers.com draws investors' attention tothe Biotech space, which is characterized by long development lead times, as it can take as much as a decade to get a new drug from test tube to pharmacy shelf. Companies under assessment are: Trevena Inc. (NASDAQ: TRVN), Ocular Therapeutix Inc. (NASDAQ:
On Thursday, shares in King of Prussia, Pennsylvania headquartered Trevena Inc. recorded a trading volume of 661,095 shares. The stock ended the session 2.95% lower at $3.29. The Company's shares are trading 8.42% below their 50-day moving average. Moreover, shares of Trevena, which develops various therapies based on breakthrough science to benefit patients and healthcare providers confronting serious medical conditions, have a Relative Strength Index (RSI) of 43.48.
On May 04th, 2017, Trevena announced financial results for the quarter ended March 31st, 2017. The Company reported a net loss attributable to common stockholders of $20.7 million for Q1 2017; research and development expenses of $16.1 million; general and administrative expenses of $4.9 million; and cash, cash equivalents and marketable securities of $97.9 million. The free research report on TRVN is available at:
Bedford, Massachusetts headquartered Ocular Therapeutix Inc.'s stock closed the day flat at $9.10 with a total trading volume of 483,733 shares. The Company's shares have advanced 5.81% in the past month, 32.46% in the previous three months, and 8.72% since the start of this year. The stock is trading 2.54% and 18.82% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Ocular Therapeutix, which focuses on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology in the US, have an RSI of 52.32.
On May 02nd, 2017, Ocular Therapeutix announced that 11 abstracts on drug-product candidates incorporating its proprietary hydrogel platform technology will be presented on May 07th, 2017 to May 11th, 2017 at the Association for Research in Vision and Ophthalmology Annual Meeting in Baltimore, MD. Clinical data on some of the Company's current pipeline products, including DEXTENZA™ (dexamethasone insert) 0.4 mg, OTX-TP (travoprost insert), and OTX-TKI (tyrosine kinase inhibitor), will be presented during the conference. The complimentary report on OCUL can be downloaded at:
Shares in Chandler, Arizona headquartered INSYS Therapeutics Inc. recorded a trading volume of 331,562 shares. The stock ended yesterday's trading session 0.75% lower at $10.65. The Company's shares have advanced 5.65% in the past month, 7.68% in the previous three months, and 15.76% on an YTD basis. The stock is trading below its 50-day moving average by 3.00%. Furthermore, shares of INSYS Therapeutics, which develops and commercializes supportive care products, have an RSI of 47.13.
On April 25th, 2017, INSYS Therapeutics announced that it will release its Q1 2017 financial results on Tuesday, May 09th, 2017, before the US financial markets open. Following the release of the financial results, Saeed Motahari, President and CEO, and Darryl S. Baker, CFO, will host a conference call at 10:00 a.m. EDT. Visit us today and download our complete research report on INSY for free at:
Austin, Texas-based Pain Therapeutics Inc.'s stock finished Thursday's session 4.33% lower at $0.78 with a total trading volume of 176,202 shares. The Company's shares have advanced 38.04% over the previous three months and 37.14% since the start of this year. The stock is trading above its 50-day moving average by 2.67%. Additionally, shares of Pain Therapeutics, which develops drugs for treating nervous system in the US, have an RSI of 49.97.
On April 25th, 2017, Pain Therapeutics reported financial results for Q1 2017. Net loss was $2.7 million for the quarter; net cash used was $1.5 million; research and development expenses decreased to $1.4 million; and general and administrative expenses decreased to $1.4 million. Get free access to your technical report on PTIE at:
Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
SC has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Parotidectomy is a surgery to remove a part of or the entire parotid salivary gland, on the side of ...
Brugada syndrome is a rare genetic heart condition that affects the way electrical signals pass ...
Modified Atkins diet designed for weight loss and to treat seizures is high in fat and low in ...View All